Abbott And Alza Will Discuss Ditropan XL Copromotion In Merger Post-Mortem
Executive Summary
Abbott and Alza are discussing whether the five-year copromotion agreement for Alza's Ditropan XL (oxybutynin) will survive the Dec. 16 collapse of the pending merger.
You may also be interested in...
ImClone/Bristol Due Diligence Lesson: FDA Review Divisions Need Closer Look
Changes at FDA review divisions deserve closer scrutiny as part of due diligence efforts for in-licensing deals, panelists at a BIO/Windhover conference in Washington D.C. suggested
ImClone/Bristol Due Diligence Lesson: FDA Review Divisions Need Closer Look
Changes at FDA review divisions deserve closer scrutiny as part of due diligence efforts for in-licensing deals, panelists at a BIO/Windhover conference in Washington D.C. suggested
Bayer To Market Alza Viadur In U.S.; Weighs International Agreement
Bayer is considering an international marketing arrangement for Alza's Viadur following an agreement to market the long-acting leuprolide acetate implant for prostate cancer in the U.S.